IMWG Releases 2024 RRMM CAR-T Guidelines: Equecabtagene Autoleucel Becomes China’s First Included CAR-T Therapy

###IMWG Releases 2024 RRMM CAR-T Guidelines: Equecabtagene Autoleucel Becomes China’s First Included CAR-T Therapy

IMWG

###EquecabtageneAutoleucel: Leading China’s CAR-T Therapy to Global Breakthroughs

In the latest guidelines released by the International Myeloma Working Group (IMWG) in 2024, Equecabtagene Autoleucel, a CAR-T therapy independently developed in China, has been officially included. This marks the first and only Chinese CAR-T product included in the global treatment guidelines for relapsed and refractory multiple myeloma (RRMM). This milestone signifies a major breakthrough for China in the field of CAR-T therapy and brings new hope to RRMM patients worldwide.

####CARTTherapy: A New Hope for Multiple Myeloma Patients

Multiple myeloma (MM) is a challenging blood cancer to treat, with approximately 176,404 new cases and 117,077 related deaths globally in 2020. Traditional therapies have limited effectiveness for relapsed and refractory MM patients. The emergence of CAR-T cell therapy has brought significant treatment progress for this group. CAR-T therapy reprograms the patient’s own T cells to recognize and kill cancer cells, achieving remission rates of 73%-98%.

#### Equecabtagene Autoleucel: A Unique Fully Human CAR-T Product

Equecabtagene Autoleucel is the only fully human CAR-T product included in the “2024 IMWG RRMM CAR-T Guidelines.” Compared to the other two included CAR-T products, which are derived from mice and alpacas (ide-cel and cilta-cel), Equecabtagene Autoleucel’s unique design reduces immunogenicity while enhancing efficacy. Since its launch in China, it has demonstrated significant therapeutic effects and safety, with a total response rate of 98.9%, a complete response rate of 82.4%, and a one-year progression-free survival rate of 85.5%.

#### Global Recognition: The Significance of IMWG Guidelines

The IMWG guidelines are developed by top global experts in multiple myeloma, providing the latest research findings and best practice recommendations for CAR-T therapy. The “2024 IMWG RRMM CAR-T Guidelines” not only recognize the excellent efficacy of Equecabtagene Autoleucel but also offer detailed guidance on patient selection and safety management, covering the management of unique toxicities such as cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) during treatment.

#### Looking Ahead: Benefiting More Patients

The inclusion of Equecabtagene Autoleucel in the IMWG guidelines showcases China’s leading position in CAR-T therapy development and will help further expand its application globally. This achievement is a significant breakthrough for China’s biopharmaceutical field and brings new treatment hope for RRMM patients worldwide. With ongoing clinical research and real-world data accumulation, Equecabtagene Autoleucel is expected to benefit more patients domestically and internationally, continuously advancing CAR-T therapy.

In the global treatment landscape for multiple myeloma, Equecabtagene Autoleucel is at the forefront, bringing new hope to countless patients. Stay tuned to Equecabtagene Autoleucel and witness the outstanding innovation and global impact of China’s biopharmaceutical industry!

🎉🎉To assess whether the condition is suitable for CAR-T or clinic therapy, you can submit Advanced Medicine in China  for preliminary evaluation!

WhatsApp: +8613717959070

Email: doctor.huang@globecancer.com

#EquecabtageneAutoleucel #CART #MultipleMyeloma #CancerTreatment #Biopharmaceuticals #IMWG2024 #MedicalBreakthrough #InnovativeTherapy #GlobalHealthcare #CancerResearch #PatientHope #ChineseMedicine #Immunotherapy